Last reviewed · How we verify
TQB3602
At a glance
| Generic name | TQB3602 |
|---|---|
| Sponsor | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Clinical Trial of the TQB3602 Capsule Combined With AK105 Injection in Patients With Advanced Cancers (PHASE1)
- A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3602 Capsule (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TQB3602 CI brief — competitive landscape report
- TQB3602 updates RSS · CI watch RSS
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. portfolio CI